| ¿µ¹® | prothrombin time | ÇÑ±Û | ÇÁ·ÎÆ®·Òºó½Ã°£ |
|---|---|---|---|
| ¼³¸í | ÇÁ·ÎÆ®·ÒºóÀº °£¿¡¼ ÇÕ¼ºµÇ´Â ºñŸ¹Î K ÀÇÁ¸¼º ÀÀ°í´Ü¹éÁúÀÇ ÇϳªÀ̸ç, ÇÁ·ÎÆ®·Òºó½Ã°£Àº ¿ÜÀΰè ÀÀ°íȰ¼ºÀ» Á¾ÇÕÀûÀ¸·Î ƯÁ¤ÇÏ´Â °Ë»çÀÇ ÇϳªÀÌ´Ù. ÇǰËÇ÷Àå¿¡ Ä®½·À̿°ú Á¶Á÷Æ®·Òº¸ÇÃ¶ó½ºÆ¾(Á¦III ÀÀ°íÀÎÀÚ)À» °¡ÇØ, ¼¶À¯¼Ò°¡ ³ªÅ¸³¯ ¶§±îÁöÀÇ ½Ã°£À¸ ÃøÁ¤ÇÑ´Ù. |
||
| SDT | sensory detection theory; right sacrotransverse [fetal position] [Lat. sacrodextra transversa]; sign... |
|---|---|
| PPDs | (Tuberculin) Purified Protein Derivatives |
| PPCA | plasma prothrombin conversion accelerator; proserum prothrombin conversion accelerator |
| DOI | date of injury; died of injuries; diffusion of innovations [theory] |
| MAUT | multi-attribute utility theory |
| DFT | Density Functional Theory |
|---|---|
| IRT | Item Response Theory |
| SDT | Signal Detection Theory |
| TOM | Theory of Mind |
| TPB | Theory of Planned Behavior |
| atropine derivatives | Analogs and derivatives of atropine. (12 Dec 1998) |
|---|---|
| water-soluble chlorophyll derivatives | The copper complex of sodium and/or potassium salts of saponified chlorophyll, used topically for deodorization of chronic lesions and to promote wound repair. (05 Mar 2000) |
| morphine derivatives | Analogs or derivatives of morphine. (12 Dec 1998) |
| scopolamine derivatives | Analogs or derivatives of scopolamine. (12 Dec 1998) |
| indanedione derivatives | Anticoagulants similar to warfarin in action. Anisindione and phenindione are clinically used; diphenadione is very long acting and used as a rodenticide. (05 Mar 2000) |
| ergotamine derivatives | Analogs and derivatives of ergotamine. (12 Dec 1998) |
| proserum prothrombin conversion accelerator | A coagulation (clotting) factor. Classic haemophilia (haemophilia A) is due to a congenital deficiency in the amount (or activity) of factor VIII. Factor VIII is also known as antihemophiliac factor (AHF) or antihemophiliac globulin (AHG). The gene for factor VIII (that for classic haemophilia) is on the X chromosome so females can be silent carriers without symptoms and males can be haemophiliacs. (12 Dec 1998) |
| prothrombin | Clotting Factor II. Origin: Gr. Thrombos = cloth in (18 Nov 1997) |
| prothrombin accelerator | <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease. Chemical name: Blood-coagulation factor V (12 Dec 1998) |
| prothrombin and proconvertin test | A test formerly used by some to control anticoagulant therapy with bishydroxycoumarin and indandione drugs. Synonym: P and P test. (05 Mar 2000) |
| prothrombin deficiency | A congenital or acquired disorder of blood clotting where there is a deficiency of factor II (prothrombin), one of 20 necessary plasma proteins for normal blood coagulation. Acquired factor II deficiency may result from vitamin K deficiency, severe liver disease and anticoagulant drugs. Symptoms include abnormal bleeding, nosebleeds, abnormal menstrual bleeding, easy bruising and umbilical cord bleeding at birth. Treatment involves the infusion of fresh frozen plasma. Vitamin K may be administered in select cases. (27 Sep 1997) |
| prothrombin test | A quantitative test for prothrombin in the blood based on the clotting time of oxalated blood plasma in the presence of thromboplastin and calcium chloride; measures the integrity of the extrinsic and common pathways of coagulation. See: prothrombin time. Synonym: Quick's method, Quick's test. (05 Mar 2000) |
| prothrombin time | Measurement of clotting time of plasma recalcified in the presence of excess tissue thromboplastin. Factors measured are fibrinogen, prothrombin, and factors v, vii, and x. It is used for monitoring anticoagulant therapy with coumarins. (12 Dec 1998) |
| serum prothrombin conversion accelerator | <chemical> Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor viia in the extrinsic pathway of blood coagulation. The activated form then catalyses the activation of factor x to factor xa. Chemical name: Blood-coagulation factor VII (12 Dec 1998) |
| Abbe theory of image formation | <optics, physics> Abbe's theory is based on the fact that a non-self-luminous particle, which is illuminated by an extraneous source, gives rise to diffracted light rays, in addition to the dioptric pencil. He stated that to form a good microscopical image as many of the diffracted rays as possible should be intercepted by the objective. With closely ruled lines, his theory is easily demonstrated by observing the back lens of the objective, for here the diffracted rays can be observed directly if the aperture diaphragm is closed. It can be shown that, when the illumination is arranged to exclude the diffracted images, resolution is lost. (11 Mar 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|